Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Carnaz Simões AM"'
Autor:
Hansen UK; Section of Experimental and Translational Immunology, Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.; PokeAcell Aps, BioInnovation Institute, Copenhagen, Denmark., Church CD; Department of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA., Carnaz Simões AM; PokeAcell Aps, BioInnovation Institute, Copenhagen, Denmark., Frej MS; Section of Experimental and Translational Immunology, Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.; PokeAcell Aps, BioInnovation Institute, Copenhagen, Denmark., Bentzen AK; Section of Experimental and Translational Immunology, Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark., Tvingsholm SA; Section of Experimental and Translational Immunology, Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark., Becker JC; Department of Translational Skin Cancer Research, University Hospital Essen and German Cancer Consortium (DKTK), Essen, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, University Hospital Essen, Essen, Germany., Fling SP; Fred Hutchinson Cancer Center, Seattle, Washington, USA., Ramchurren N; Fred Hutchinson Cancer Center, Seattle, Washington, USA., Topalian SL; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA., Nghiem PT; Department of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, USA.; Fred Hutchinson Cancer Center, Seattle, Washington, USA., Hadrup SR; Section of Experimental and Translational Immunology, Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
Publikováno v:
The Journal of clinical investigation [J Clin Invest] 2024 Jan 30; Vol. 134 (8). Date of Electronic Publication: 2024 Jan 30.
Autor:
Carnaz Simões AM; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark., Holmström MO; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark., Aehnlich P; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark., Rahbech A; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark., Radziwon-Balicka A; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark., Zamora C; IIB-Sant Pau- Institut Rec. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Wirenfeldt Klausen T; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark., Skov V; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Kjær L; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Ellervik C; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.; Department of Data and Innovation Support, Region Zealand, Sorø, Denmark., Fassi DE; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Hematology, Rigshospitalet University Hospital, Copenhagen, Denmark., Vidal S; IIB-Sant Pau- Institut Rec. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Hasselbalch HC; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Andersen MH; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark.; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Thor Straten P; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark.; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Publikováno v:
Frontiers in immunology [Front Immunol] 2022 May 06; Vol. 13, pp. 866610. Date of Electronic Publication: 2022 May 06 (Print Publication: 2022).
Autor:
Holmen Olofsson G; National Center for Cancer Immune Therapy, CCIT-DK, Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark., Idorn M; National Center for Cancer Immune Therapy, CCIT-DK, Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.; Department of Biomedicine, Aarhus University, Aarhus, Denmark., Carnaz Simões AM; National Center for Cancer Immune Therapy, CCIT-DK, Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark., Aehnlich P; National Center for Cancer Immune Therapy, CCIT-DK, Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark., Skadborg SK; National Center for Cancer Immune Therapy, CCIT-DK, Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark., Noessner E; Helmholtz Zentrum München, Germany Research Center for Environmental Health, Immunoanalytics, Research Group Tissue control of immunocytes, Munich, Germany., Debets R; Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC-Cancer Center, Rotterdam, Netherlands., Moser B; Division of Infection & Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom., Met Ö; National Center for Cancer Immune Therapy, CCIT-DK, Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Thor Straten P; National Center for Cancer Immune Therapy, CCIT-DK, Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark.; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Publikováno v:
Frontiers in immunology [Front Immunol] 2021 Jun 02; Vol. 12, pp. 645131. Date of Electronic Publication: 2021 Jun 02 (Print Publication: 2021).
Autor:
Jensen AWP; National Center for Cancer Immune Therapy (DK-CCIT), Department of Oncology, University Hospital, DK-2730 Herlev, Denmark., Carnaz Simões AM; National Center for Cancer Immune Therapy (DK-CCIT), Department of Oncology, University Hospital, DK-2730 Herlev, Denmark., Thor Straten P; National Center for Cancer Immune Therapy (DK-CCIT), Department of Oncology, University Hospital, DK-2730 Herlev, Denmark.; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark., Holmen Olofsson G; National Center for Cancer Immune Therapy (DK-CCIT), Department of Oncology, University Hospital, DK-2730 Herlev, Denmark.
Publikováno v:
Cancers [Cancers (Basel)] 2021 Jan 21; Vol. 13 (3). Date of Electronic Publication: 2021 Jan 21.
Autor:
Aehnlich P; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital Herlev, Herlev, Denmark., Carnaz Simões AM; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital Herlev, Herlev, Denmark., Skadborg SK; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital Herlev, Herlev, Denmark., Holmen Olofsson G; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital Herlev, Herlev, Denmark., Thor Straten P; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital Herlev, Herlev, Denmark.; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Publikováno v:
Frontiers in immunology [Front Immunol] 2020 Aug 28; Vol. 11, pp. 1868. Date of Electronic Publication: 2020 Aug 28 (Print Publication: 2020).
Autor:
Peeters MJW; Department of Hematology, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark. per.thor.straten@regionh.dk marlies.peeters@regionh.dk., Dulkeviciute D; Department of Hematology, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark., Draghi A; Department of Hematology, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark., Ritter C; Translational Skin Cancer Research, University Hospital Essen, German Cancer Consortium (DKTK) Partner Site Essen and German Cancer Research Center (DKFZ), Heidelberg, Germany., Rahbech A; Department of Hematology, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark., Skadborg SK; Department of Hematology, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark., Seremet T; Department of Hematology, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark., Carnaz Simões AM; Department of Hematology, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark., Martinenaite E; Department of Hematology, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark., Halldórsdóttir HR; Department of Hematology, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark., Andersen MH; Department of Hematology, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark., Olofsson GH; Department of Hematology, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark., Svane IM; Department of Hematology, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark.; Department of Oncology, University Hospital Herlev, Copenhagen, Denmark., Rasmussen LJ; Department of Cellular and Molecular Medicine, Center for Healthy Aging, University of Copenhagen, Denmark., Met Ö; Department of Hematology, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark.; Department of Oncology, University Hospital Herlev, Copenhagen, Denmark.; Department of Immunology and Microbiology, Inflammation and Cancer Group, University of Copenhagen, Copenhagen, Denmark., Becker JC; Translational Skin Cancer Research, University Hospital Essen, German Cancer Consortium (DKTK) Partner Site Essen and German Cancer Research Center (DKFZ), Heidelberg, Germany., Donia M; Department of Hematology, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark.; Department of Oncology, University Hospital Herlev, Copenhagen, Denmark., Desler C; Department of Cellular and Molecular Medicine, Center for Healthy Aging, University of Copenhagen, Denmark., Thor Straten P; Department of Hematology, Center for Cancer Immune Therapy, University Hospital Herlev, Copenhagen, Denmark. per.thor.straten@regionh.dk marlies.peeters@regionh.dk.; Department of Immunology and Microbiology, Inflammation and Cancer Group, University of Copenhagen, Copenhagen, Denmark.
Publikováno v:
Cancer immunology research [Cancer Immunol Res] 2019 Sep; Vol. 7 (9), pp. 1472-1484. Date of Electronic Publication: 2019 Jul 02.